Scholar Rock Holding (SRRK) EPS (Weighted Average and Diluted) (2020 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly EPS (Weighted Average and Diluted) of -$0.83 in Q1 2026, down 10.67% quarter-over-quarter from -$0.75 in Q4 2025, and down 23.88% on a YoY basis from -$1.09 in Q1 2025.
Scholar Rock Holding (SRRK) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Scholar Rock Holding's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.83 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 23.88% year-over-year to -$0.83; the TTM figure through Mar 2026 stood at -$3.46 (down 36.22% YoY), while the FY2025 annual figure was -$3.29, down 33.2% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.83 for Q1 2026 at Scholar Rock Holding, down from -$0.75 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.21 in Q1 2022 to a low of -$1.06 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.64 across 5 years, with a median of -$0.6 in 2024.
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) jumped 72.37% in 2022, then tumbled 133.33% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.46 in 2022, then fell by 8.7% to -$0.5 in 2023, then dropped by 22.0% to -$0.61 in 2024, then fell by 22.95% to -$0.75 in 2025, then retreated by 10.67% to -$0.83 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.83 (Q1 2026), -$0.75 (Q4 2025), and -$0.9 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -0.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.83 |
| Dec 31, 2025 | -0.75 |
| Sep 30, 2025 | -0.90 |
| Jun 30, 2025 | -0.98 |
| Mar 31, 2025 | -0.67 |
| Dec 31, 2024 | -0.61 |
| Sep 30, 2024 | -0.66 |
| Jun 30, 2024 | -0.60 |
| Mar 31, 2024 | -0.59 |
| Dec 31, 2023 | -0.50 |
| Sep 30, 2023 | -0.53 |
| Jun 30, 2023 | -0.47 |
| Mar 31, 2023 | -0.49 |
| Dec 31, 2022 | -0.46 |
| Sep 30, 2022 | -0.55 |
| Jun 30, 2022 | -1.06 |
| Mar 31, 2022 | -0.21 |
| Dec 31, 2021 | -0.97 |
| Sep 30, 2021 | -1.02 |
| Jun 30, 2021 | -0.84 |